Vice President, Clinical Biomarkers and CDx, BioPharma
5 free lookup(s).
David Shames Location
California, United States
David Shames Work
2026 -
now Vice President, Clinical Biomarkers and CDx, BioPharma @ Natera, Inc
2024 -
2026 VP, Global Head of Clinical Biomarkers and CDx Development @
2021 -
2024 Executive Director and Senior Fellow @
2020 -
2021 Executive Director and Staff Scientist @
2018 -
2021 Staff Scientist @
2019 -
2020 Senior Director and Staff Scientist @
2015 -
2018 Principal Scientist @
2013 -
2015 Senior Scientist @
2009 -
2013 Scientist @
2006 -
2009 Post-doc @
David Shames Education
UT Southwestern Medical Center
PhD (Cancer Biology)
2001
-
2006
Columbia University
(Molecular Biology)
2000
-
2001
University of Pennsylvania
BA (Environmental Studies / Geology)
1993
-
1998
Aiglon College 1989
-
1993
David Shames Skills
Biochemistry
Molecular Biology
Biotechnology
Life Sciences
Cell Biology
Cell Culture
Drug Discovery
Western Blotting
PCR
Oncology
Drug Development
Companion Diagnostics
Biomarkers
FDA
Clinical Research
Strategic Planning
Microsoft Excel
Pharmaceutical Industry
Cancer Immunotherapy
Group Medical
David Shames Summary
David Shames, based in California, United States, is currently a Vice President, Clinical Biomarkers and CDx, BioPharma at Natera, Inc. David Shames brings experience from previous roles at BeOne Medicines and Genentech. David Shames holds a 2001 - 2006 PhD in Cancer Biology @ UT Southwestern Medical Center. With a robust skill set that includes Biochemistry, Molecular Biology, Biotechnology, Life Sciences, Cell Biology and more. David Shames has 2 mobile phone numbers on RocketReach.
Get contact details of over 700M profiles across 60M companies - all with industry-leading accuracy. Sales and Recruiter users, try out our Email Finder Extension.
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.